Literature DB >> 14580936

Thymulin reverses inflammatory hyperalgesia and modulates the increased concentration of proinflammatory cytokines induced by i.c.v. endotoxin injection.

B Safieh-Garabedian1, C I Ochoa-Chaar, S Poole, C A Massaad, S F Atweh, S J Jabbur, N E Saadé.   

Abstract

The immunomodulatory thymic hormone thymulin has been shown previously to possess anti-inflammatory actions in the periphery. In this study, we have examined the effect of i.c.v. injections of either endotoxin (ET) or thymulin, in separate groups of conscious rats, on pain-related behavior and cytokine levels in different areas of the brain. Furthermore, we investigated the effect of pretreatment with either i.c.v. or i.p. injections of thymulin on endotoxin-induced hyperalgesia and the effect of pretreatment with i.c.v. thymulin on endotoxin-induced up-regulation of cytokine levels. Our results demonstrate that i.c.v. injection of endotoxin (1 microg in 5 microl saline) resulted in a significant decrease in the nociceptive thresholds as assessed by different pain tests, with peak hyperalgesia at 3 h. However, thymulin at different doses, when injected (i.c.v.), had no significant effect on pain related behavior. Pretreatment (i.c.v.) with thymulin (0.1, 0.5 and 1 microg in 5 microl saline) 20 min before endotoxin (i.c.v.) injection (1 microg in 5 microl saline) reduced, in a dose dependent manner, the endotoxin-induced hyperalgesia and exerted differential effects on the up-regulated levels of cytokines in different areas of the brain. The results provide behavioral and immunochemical characterization of a rat model for intracerebral inflammation and indicates a neuroprotective role for thymulin in the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580936     DOI: 10.1016/s0306-4522(03)00500-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

1.  Thymulin-based gene therapy and pituitary function in animal models of aging.

Authors:  Paula C Reggiani; Brenda Poch; Gloria M Cónsole; Omar J Rimoldi; Jose I Schwerdt; Victoria Tüngler; Margarita M Garcia-Bravo; Mireille Dardenne; Rodolfo G Goya
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

2.  Plasma thymulin and nerve growth factor levels in patients with primary open angle glaucoma and elevated intraocular pressure.

Authors:  Baha' N Noureddin; Christiane E Al-Haddad; Ziad Bashshur; Bared Safieh-Garabedian
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-11       Impact factor: 3.117

3.  Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice.

Authors:  Rodolfo G Goya; Paula C Reggiani; Silvan M Vesenbeckh; Jean M Pléau; Yolanda E Sosa; Gloria M Cónsole; Rüdiger Schade; Peter Henklein; Mireille Dardenne
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-03-27       Impact factor: 4.310

Review 4.  The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin.

Authors:  Paula C Reggiani; Gustavo R Morel; Gloria M Cónsole; Claudio G Barbeito; Silvia S Rodriguez; Oscar A Brown; Maria Jose Bellini; Jean-Marie Pléau; Mireille Dardenne; Rodolfo G Goya
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.